These featured cancer clinical trials are currently open at the UCI Health Chao Family Comprehensive Cancer Center.

To refer a patient or get more information about a clinical trial, click on the principal investigator’s name to send an email. You may also contact us at ucstudy@uci.edu or 877-UC-Study. To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts

**Brain and nervous system**

A phase 2 study of the PARP inhibitor olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors (ETCTN-10129)

*Principal investigator: Xiao-Tang Kong, MD*

A phase 2 trial of SMO/AKT/NF2/CDK inhibitors in progressive meningiomas with SMO/AKT/NF2/CDK pathway mutations (A071401)

*Principal investigator: Daniela Bota, MD*

**Breast**

A phase 2 trial of radium-223 dichloride in combination with paclitaxel in patients with metastatic breast cancer that has spread to the bones (ETCTN-10302)

*Principal investigator: Ritesh Parajuli, MD*

A phase 2, open-label trial of neo-adjuvant abemaciclib with fulvestrant in patients who develop localized recurrence while on adjuvant endocrine therapy with molecular
Principal investigator: Ritesh Parajuli, MD

COVID-19

NCI COVID-19 in Cancer Patients Study (NCCAPS): a longitudinal natural history study (NCICovid)
Principal investigator: Hannah Hyochan Nam, MD

Gastrointestinal

A phase 2a, multicenter, open-label study of DKN-01 in combination with tislelizumab + chemotherapy as first-line or second-line therapy in adult patients with inoperable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (DisTinGuish) (UCI 20-63/DEK-DKK1-P205)
Principal investigator: Farshid Dayyani, MD

A proof-of-concept study of ctDNA-guided change in treatment for refractory minimal residual disease in colon adenocarcinomas (UCI 20-43/NCT04920032)
Principal investigator: Farshid Dayyani, MD

Genitourinary

A phase 3 study of CG0070 in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) (UCI 20-210/CG3002S)
Principal investigator: Edward Uchio, MD

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (UCI 18-138/SGN22E-002)
Principal investigator: Nataliya Mar, MD

A phase 2 study of olaparib (AZD2281) in patients with metastatic/advanced urothelial carcinoma with DNA-repair defects (ETCTN-10144)
Principal investigator: Arash Rezazadeh Kalebasty, MD

Gynecologic oncology

A randomized, phase 2 study of bevacizumab and either weekly anetumab ravidansine or weekly paclitaxel in platinum-resistant or platinum-refractory ovarian cancer (ETCTN-10150)
Principal investigator: Jill Tseng, MD
A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-56-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/AVBS00-OC-004)

*Principal investigator: Fabio Cappuccini, MD*

**Head and neck**

Randomized, phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (HN001)

*Principal investigator: Rupali Nabar, MD*

A randomized, phase 2/3 trial of adjuvant radiation therapy with cisplatin, docetaxel-cetuximab or cisplatin-atezolizumab in pathologic, high-risk squamous cell cancer of the head and neck (RTOG-1216)

*Principal investigator: Rupali Nabar, MD*

**Hematologic malignancies**

A phase 3, randomized, double-blind trial to evaluate the efficacy of uproleselan administered with chemotherapy vs. chemotherapy alone in patients with relapsed/refractory acute myeloid leukemia (UCI 20-07/GMI-1271-301)

*Principal investigator: Pamela Sue Becker, MD*

A phase 1, multicenter, open-label study of CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (ANTLER) (UCI 20-126/CB10A)

*Principal investigator: Susan O'Brien, MD*

**Hepatobiliary**

A randomized, multicenter, subject-and-evaluator-blinded, parallel-group study to evaluate the safety and effectiveness of the Instylla Hydrogel Embolic System (HES) compared with standard-of-care transcatheter arterial embolization (TAE)/transcatheter arterial chemoembolization (cTACE) for vascular occlusion of hypervascular tumors; a pivotal study (INY-P-20-001) (UCI 20-84/INY-P-20-001)

*Principal investigator: Nadine Abi-Jaoudeh, MD*

A phase 1/2 study of M3814 (peposertib) in combination with hypofractionated
radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma (ETCTN-10366)

Principal investigator: Farshid Dayyani, MD

Lung

A phase 3, randomized study of amivantamb and lazertinib combination therapy vs. single-agent osimertinib or lazertinib as a first-line treatment in patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (UCI 20-92/73841937NSC3003)

Principal investigator: Sai-Hong Ou, MD

A randomized, open-label, phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy compared with carboplatin-pemetrexed in patients with EGFR exon 20 insertion mutated, locally advanced or metastatic non-small cell lung cancer (UCI 20-102/61186372NSC3001)

Principal investigator: Sai-Hong Ou, MD

Skin

A phase 1/2 study of dabrafenib, trametinib and navitoclax in BRAF-mutant melanoma (phase 1 and 2) and other solid tumors (phase 1 only) (ETCTN-9466)

Principal investigator: Jennifer Valerin, MD

A phase 2 study to investigate the efficacy and safety of PVSRIPO with and without immune checkpoint blockade in patients with advanced PD-1 refractory melanoma (UCI 20-174/LUMINOS-102)

Principal investigator: Jennifer Valerin, MD
As an NCI-designated comprehensive cancer center, the UCI Chao Family Comprehensive Cancer Center conducts many clinical trials. By participating in a clinical trial, your patients have access to leading-edge treatments and therapies long before they are available to the general public. According to the National Comprehensive Cancer Network (NCCN) guidelines, the best management for any cancer patient is on a clinical trial.